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The Nef Protein of HIV-1 Induces Loss of Cell Surface
Costimulatory Molecules CD80 and CD86 in APCs1
Ashutosh Chaudhry,2* Suman Ranjan Das,2† Amjad Hussain,† Satyajit Mayor,‡ Anna George,*
Vineeta Bal,* Shahid Jameel,3† and Satyajit Rath3*
The Nef protein of HIV-1 is essential for its pathogenicity and is known to down-regulate MHC expression on infected cell surfaces.
We now show that Nef also redistributes the costimulatory molecules CD80 and CD86 away from the cell surface in the human
monocytic U937 cell line as well as in mouse macrophages and dendritic cells. Furthermore, HIV-1-infected U937 cells and human
blood-derived macrophages show a similar loss of cell surface CD80 and CD86. Nef colocalizes with MHC class I (MHCI), CD80,
and CD86 in intracellular compartments, and binds to both mouse and human CD80 and CD86. Some Nef mutants defective in
MHCI down-modulation, including one from a clinical isolate, remain capable of down-modulating CD80 and CD86. Nef-mediated
loss of surface CD80/CD86 is functionally significant, because it leads to compromised activation of naive T cells. This novel
immunomodulatory role of Nef may be of potential importance in explaining the correlations of macrophage-tropism and Nef with
HIV-1 pathogenicity and immune evasion. The Journal of Immunology, 2005, 175: 4566–4574.
E stablishment of infection in vivo by HIV-1 is more effi-cient for macrophage-tropic viral strains (1). HIV-1 alsoinfects dendritic cells (DCs)4 (2). Strains of the related
SIV that induce lytic infection in macrophages show less efficient
infection in vivo than strains that cause persistent productive in-
fection in macrophages (3). HIV/SIV strains defective in the nef
gene, encoding the multifunctional accessory Nef protein, are also
attenuated in their ability to cause persistent infection and disease
(4–6). Nef inhibits the death of infected macrophages and DCs to
create a cellular reservoir of persistent infection (7). It also induces
pathways for attracting and activating T cells (8–10) to prime them
for viral infection, leading to in vivo amplification of infection. In
such a situation, a viral strategy to inhibit the resulting inevitable
antiviral T cell priming would be crucial. Because it efficiently
removes both MHC class I (MHCI) and MHC class II (MHCII)
from the cell surface (11–13), Nef is likely to contribute to immune
evasion. However, these effects alone may not mediate efficient
immune evasion, because Nef does not affect surface levels of all
MHCI isotypes or nonclassical MHC molecules (14, 15). Further-
more, Nef down-modulates MHC molecules after they reach the
cell surface, potentially allowing some presentation of antigenic
peptides. Because costimulatory signals are also essential for ef-
fective priming of naive T cells (16), we have assessed the effect
of Nef on the cell surface levels of the major costimulatory mol-
ecules on APCs such as macrophages or DCs, namely, the proteins
of the B7 family, CD80 and CD86 (17). We find that Nef also
mediates a loss of CD80 and CD86 from the APC surface. This
effect does not involve residues in Nef that are crucial for MHCI
down-regulation. Nef associates in cells with CD80 and CD86.
Significantly, a clinical isolate of HIV-1 carries a mutant Nef that
retains MHCI at the cell surface, but efficiently down-modulates
CD80 and CD86, with functional consequences for naive T cell
activation.
Materials and Methods
Wild-type (WT) and mutant nef genes and plasmids
The F2-nef and D1-nef genes from Indian HIV-1 subtype C primary iso-
lates have been described earlier (18). These and other nef mutant genes
described below were subcloned into the bicistronic mammalian expres-
sion vector pIRES2-eGFP (BD Clontech), or expressed as nef-eGFP fusion
genes by ligating the nef gene inserts into the plasmid peGFP-N3 (BD
Clontech), or were expressed in the pMT3 expression vector (BD Clontech)
after tagging with the influenza virus hemagglutinin epitope (HAp). The
primers used for HAp tagging were: forward, CTGCAGATGTACCCAT
ACGATGTTCCAGATTACGCT; reverse, CGGAATTCAGCAGTCTT
TGTAGAACTC.
Truncation mutants of nef were made by PCR amplification of the 100
and 125 fragments from the cloned F2-nef gene. The primers used were:
WT F2-nef CGGGATCCAATGGGTGGCAAGTGGTCAA (outer for-
ward), CGGAATTCAGCAGTCTTTGTAGAACTC (outer reverse), CG
GAATTCATGGGTGGCAAGTGGTCAAAAT (inner forward), CGGG
TACCTCAGCAGTCTTTGTAGAACTCCG (inner reverse); 100 F2-nef
CGGGATCCAATGGGTGGCAAGTGGTCAA (forward), GCGGATC
CAATTTACCCTTCCAGTCCCCC (reverse); 125 F2nef CGGGATC
CAATGGGTGGCAAGTGGTCAA (forward), GCGGATCCAATTTA
CCCTTCCAGTCCCCC (reverse).
The PCR-amplified fragments were subsequently cloned into the
pIRES2-eGFP or peGFP-N3 vectors (BD Clontech). The G2A mutant of
F2-nef was made by PCR amplification using the primers: forward, CG
GAATTCATGGCTGCGAAGTGGTCAAAATGCAGC; reverse, CGGA
ATTCAGCAGTCTTTGTAGAACTC.
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Other site-directed, single amino acid mutants were generated using the
In Vitro Mutagenesis kit (Stratagene). All constructs were verified by DNA
sequencing. The panel of HAp-tagged NL4-3 nef mutants (7) was gifted by
Dr. W. C. Greene (University of California, San Francisco, CA).
OVA plasmid
A 1.9-kb BamHI/HindIII fragment containing the c-myc-p-LCMVp-OVA-
coding sequence described earlier (19) was cloned into the BglII-HindIII
site of the expression vector pMD312 to generate a construct expressing a
GFP-c-myc-p-LCMVp-OVA fusion protein.
Animals
C57BL/6 and OT-I mice were obtained from The Jackson Laboratory. The
OT-II mice were gifted by A. Rudensky (University of Washington, Se-
attle, WA). Mice were bred and maintained in the animal facilities of the
National Institute of Immunology (New Delhi, India). All animal experi-
ments were done under the approval of the Institutional Animal Ethics
Committee.
Anti-Nef Abs
Full-length His-tagged F2-Nef protein expressed in Escherichia coli was
purified, and anti-Nef polyclonal Abs were raised in New Zealand White
rabbits using this purified rF2-Nef protein. The IgG fraction was purified
from immune sera on protein A-Sepharose (Amersham).
T cell activation assays
Activation of T cell hybridoma cells (13.8 and B3Z) was estimated by
colorimetric measurement (A570 nm) of enzymatic activity expressed from
an IL-2 promoter-driven -galactosidase (-gal) reporter gene. The acti-
vation-induced proliferation of primary TCR-transgenic OT-I or OT-II
cells was measured by [3H]thymidine incorporation. BMC-2 cells were
used as APCs 8 h after transfection at 106 cells/ml (for 13.8 or OT-II T
cells), or in titrating numbers (for B3Z and OT-I T cells). Responder T cells
were used at 106 cells/ml, and activation was estimated after coincubation
with transfected APCs for 24 h. Azide-free anti-CD80 and anti-CD86
mAbs (eBioscience) were used for functional blockade at 10 g/ml each.
Cells and transfection
BMC-2 cells were maintained in Click’s medium, with FCS, 2-ME, L-
glutamine, and antibiotics. U937 cells were maintained in RPMI 1640 me-
dium, with FCS, antibiotics, and LPS (0.5 g/ml) for maintenance of high
MHC and CD80/CD86 levels. Primary human macrophages were grown
from PBMC by culturing them with rM-CSF (100 U/ml; Sigma-Aldrich)
for 3 days, and live cells were used for infection in the continuing presence
of the growth factor. Primary macrophages and DCs were grown from
mouse bone marrow by culturing nonadherent mouse bone marrow cells
with either M-CSF (30% L929 fibroblast-conditioned medium as M-CSF
source) or rGM-CSF (PeproTech), respectively, for 9 days, with periodic
growth factor replenishment. Tightly adherent cells were excluded from the
GM-CSF-containing cultures on day 7, and live cells were used for trans-
fection on day 9. Transfections were done using Fugene6 (Roche) or Ef-
fectene (Qiagen), according to the manufacturers’ protocols, with 12 g of
plasmid DNA for 2  106 cells.
Flow cytometry
Cells were stained with primary and secondary reagents on ice for 30 min,
as appropriate. For intracellular staining, cells were permeabilized with
0.03% saponin. Stained cells were analyzed on a BD-LSR (BD Bio-
sciences) flow cytometer. Data were analyzed using FlowJo software
(Treestar).
Antibodies
The human-specific mAbs used were W6/32 for MHCI and OKT-9 for
transferrin receptor (TfR) (used as culture supernatants), and biotinylated
anti-CD80 and anti-CD86 (eBiosciences). The mouse-specific mAbs used
as culture supernantants were: Y-3 for MHCI (H-2Kb and H-2Db) and 3/23
for CD40. Other mouse-specific mAbs used were: anti-CD54 PE, anti-
CD80 biotin, anti-CD86 biotin, and anti-CD11b biotin (BD Pharmingen).
The secondary reagents used included goat anti-mouse IgG (Fc) PE and
donkey anti-rat IgG (Fc) PE (Jackson ImmunoResearch Laboratories), and
streptavidin-PE or streptavidin-CyChrome (BD Pharmingen). For studies
with HAp-tagged genes, transfected cells were stained for surface mole-
cules and then permeabilized for intracellular HAp staining using an anti-
HAp mAb (Cell Signaling Technology). Similarly, gene products with the
myc-p-tag were detected in permeabilized cells with an anti-myc-p mAb
(Cell Signaling Technology).
Confocal microscopy
For confocal microscopy, cells were grown on coverslip-bottomed dishes,
transfected, and fixed in situ with 3% paraformaldehyde, followed by sa-
ponin (0.1%) permeabilization and blocking with 1% BSA. Staining was
done on coverslips with primary and secondary reagents, as appropriate.
Confocal images were acquired on a Bio-Rad MRC-1024 confocal micro-
scope (Bio-Rad) with factory-set dichroics and a Krypton-Argon laser,
using LaserSharp software (Bio-Rad), or using a Zeiss LSM 510 Meta
confocal system equipped with Argon, HeNe, and HeCd lasers (Zeiss).
Images were processed in MetaMorph (Universal Imaging) and Adobe
Photoshop (Adobe Systems) softwares. Image quantitation was done as
described (20), using Metamorph software.
Viruses and infection
HIV-1 viral stocks were generated by electroporation of HeLa cells with
the infectious molecular clones pNL4-3, pNL4-3 FS Nef (gifted by H.
Gottlinger, University of Massachusetts Medical School, Worcester, MA),
or pNL4-3 ADA or pNL4-3 ADANef (gifted by M. Stevenson, Univer-
sity of Massachusetts Medical School, Worcester, MA). Virus stocks were
harvested 72 h later and filter sterilized. U937 cells were serum starved for
1 h before infection. For each infection, 1  106 cells were infected with
100,000–200,000 cpm of reverse-transcriptase counts of virus. After a 4-h
adsorption, cells were washed and incubated for 72 h before being stained
for surface CD80, CD86, or MHCI, and intracellular p24 gag protein.
Immunoprecipitation and Western blot analyses
Transfected cell lysates were immunoprecipitated with either anti-Nef, anti-
CD80, or anti-CD86 Abs and Western blotted for the indicated molecules
after 12% SDS-PAGE of 50 g of protein/lane and transfer. The secondary
reagents were goat anti-rabbit IgG HRP (Cell Signaling Technology) or
donkey anti-rat IgG HRP (Jackson ImmunoResearch Laboratories). Blots
were developed with the diaminobenzidine reagent (Bio-Rad).
Yeast two-hybrid analysis
The F2-nef and CD80/CD86 genes were fused to the DNA binding or
activation domains, respectively, of the yeast Gal4 protein gene. For this,
the F2-nef gene was transferred as an EcoRI-BamHI fragment to pGADT7
(BD Clontech), which expresses inserted genes as fusion proteins together
with the yeast Gal4 protein activation domain. The CD80 and CD86 genes
were PCR amplified from plasmids pBJCD80 and pBJCD86, containing
the human CD80 and CD86 genes, respectively, using the primers: CD80,
GAATTCACCATGGGCCACACACGGAGGCAG (forward), CTGCA
GTTATACAGGGCGTACACTTTCC (reverse); CD86, GGATCCAC
CATGGGACTGAGTACAATTCTCTTTGTG (forward), GTCGACAA
TTTAAAACATGTATCACTTTTGTCGCAT GAA (reverse).
These were cloned as EcoRI-PstI and BamHI-SalI fragments, respec-
tively, into pGBKT7 (BD Clontech), which expresses inserted genes as
fusion proteins to the yeast Gal4 protein DNA binding domain. The clones
were checked by restriction digestion, DNA sequencing, and protein ex-
pression using an in vitro coupled transcription-translation system (TNT;
Promega). These plasmids were cotransformed into Saccharomyces cer-
evisiae strain AH109 (MATa trp1-901 his3 leu2-3, 112 ura3-52 ade2 gal4
gal80URA3::GAL-lacZ LYS2::GAL-HIS3) containing the HIS3 and lacZ
reporter genes under the control of GAL4 binding sites. The host strain
containing plasmids pAS2-SNF1 and pACT2-SNF4 was used as a positive
control (21). Various negative controls that included single or dual trans-
formants were also run in the same assay. The transformed AH109 yeast
cells were plated on either complete yeast extract/peptone/dextrose me-
dium or synthetic dextrose in the absence of either leucine or tryptophan,
or both. Protein interaction was tested by growth on synthetic dextrose
plates without leucine, tryptophan, and histidine, and the specificity of the
interaction was tested as growth on these plates containing 20 mM 3-ami-
no-1, 2, 3-triazole. The -gal filter-lift and liquid assays were conducted,
as described elsewhere (22).
Results
HIV-1 Nef reduces cell surface CD80 and CD86 levels in
human and mouse macrophages
A WT nef gene (F2-nef) cloned from an Indian clinical isolate (18)
was used for transfection studies. In human monocytic U937 cells
expressing F2-Nef, the levels of cell surface CD80 and CD86 were
reduced 5- to 10-fold at 48 h posttransfection, along with reduction
in the surface levels of MHCI (Fig. 1A). No significant change in
the surface levels of the TfR could be detected (Fig. 1A). There
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was no reduction in the total cellular levels of any of these mol-
ecules, as measured by staining postpermeabilization (Fig. 1A).
The F2-Nef effects were based on comparison with an enhanced
GFP (eGFP) control, under conditions of comparable transfection
efficiencies of the two plasmids.
We next examined MHCI, CD80, and CD86 levels on U937
cells infected with either WT or nef-deficient strains of HIV-1
(NL4-3 strain). In HIV-infected cells, as indicated by p24gag
expression, while WT HIV-1 induced a loss of cell surface MHCI,
CD80, and CD86 levels, the nef-deficient virus did not induce any
down-regulation of these molecules (Fig. 1B). Furthermore, when
primary human monocytes from peripheral blood were grown in
M-CSF and infected with either WT or nef-deficient strains
of HIV-1 (ADA strain), the WT, but not nef-deficient HIV-1 again
induced a loss of cell surface MHCI, CD80, and CD86 levels
(Fig. 1C).
Nef expression led to a similar 5- to 6-fold reduction of surface
CD80 and CD86 in the murine monocytic BMC-2 cell line (Fig.
2A). Surface levels of two other macrophage proteins, CD11b and
CD54, were unaffected (Fig. 2A). There was no reduction in the
total cellular levels of any of these molecules (Fig. 2A). F2-Nef
had similar effects on primary nontransformed mouse bone mar-
row DCs and macrophages (Fig. 2B) as well. As earlier, the F2-Nef
effects were based on comparison with an eGFP control, under
FIGURE 1. Nef causes reduction of surface CD80 and CD86 levels in
a human monocytic cell line. A, U937 cells were transfected to express
eGFP either alone or with F2-Nef, or were mock transfected (), as indi-
cated. Two-parameter plots show the frequencies of and gates set for
eGFP cells. Histograms show surface-staining levels or postpermeabili-
zation-staining levels for the indicated molecules in cells expressing eGFP
alone or with Nef. Gray-shaded curves indicate isotype controls. B, Two-
color flow cytometric analysis for intracellular p24 protein vs cell surface
MHCI, CD80, and CD86 expression levels on U937 cells, either unin-
fected, or infected with the HIV-1 strains indicated at 72 h after infection.
C, Two-color flow cytometric analysis for intracellular p24 protein vs cell
surface MHCI, CD80, and CD86 expression levels on primary human
monocytes, either uninfected or infected with the HIV-1 strains indicated
at 72 h after infection.
FIGURE 2. Nef causes reduction of surface levels of CD80 and CD86
in mouse myeloid lineage cells. A, BMC-2 cells were transfected to express
eGFP either alone or with F2-Nef, or were mock transfected (), as indi-
cated. Two-parameter plots show the frequencies of and gates set for
eGFP cells. Histograms show surface-staining levels or postpermeabili-
zation-staining levels for the indicated molecules in cells expressing eGFP
alone or with Nef. B, Primary DCs or macrophages were transfected to
express eGFP either alone or with F2-Nef. Two-parameter plots show the
frequencies of and gates set for eGFP cells. Histograms show surface-
staining levels for the indicated molecules in cells expressing eGFP alone
or with Nef. All gray-shaded curves indicate isotype controls.
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conditions of comparable transfection efficiencies of the two
plasmids.
Nef mutants, including a clinical isolate, can differentially affect
down-modulation of MHCI vs CD80 and CD86
To further characterize Nef-mediated down-modulation of CD80/
CD86 and to identify its possible differences from MHCI down-
regulation, we tested a series of Nef mutants. Because the F2-nef
gene from an HIV-1 subtype C clinical isolate differs from the
NL4-3 HIV-1 subtype B nef gene (Fig. 3A), we constructed a num-
ber of F2-Nef mutants in addition to the available panel of NL4-
3-Nef mutants. Furthermore, we tested a variant D1-nef gene
cloned from an independent HIV-1 isolate from the same patient as
F2-nef, which has a natural deletion of residues 55–61 (numbered
according to the NL4-3 Nef sequence (Fig. 3A)).
The NL4-3-Nef mediated efficient down-regulation of MHCI,
CD80, and CD86, but a GG to AA mutation of Nef at residues 2–3
(G2A) was unable to down-regulate any of these surface proteins
(Fig. 3B). The G2A mutant protein is known to be myristoylation
deficient and is unable to associate with cellular membranes (23).
Three other mutants of NL4-3 Nef could not mediate MHCI down-
regulation, as shown earlier (24). These include an M to A muta-
tion at residue 20 (M20A), E to A mutations at residues 62 to 65
(E4A) comprising the phosphofurin acidic cluster-sorting pro-
tein-1 (PACS-1) binding domain, and P to A mutations at positions
72, 75, and 78 in the Src homology 3 (SH3)-binding PXX motifs
(Fig. 3B). However, all three mutants showed normal down-regu-
lation of CD80 and CD86 (Fig. 3B).
Like NL4-3 Nef, the G2A and M20A mutants of F2-Nef were
unable to down-regulate surface MHCI, but were fully competent
in down-regulating surface levels of CD80 and CD86 (Fig. 3C).
We then used C-terminal F2-Nef deletion mutants terminated at
residue 100 or 125 (Fig. 3A). F2-Nef truncated from residue 100
onward (F2-Nef-100) was unable to mediate any significant
down-regulation of MHCI, CD80, or CD86 (Fig. 3C). However, a
smaller C-terminal deletion from residue 125 onward (F2-Nef-
125) allowed partial down-modulation of MHCI as well as of
CD80 and CD86 (Fig. 3C). Other mutations in F2-Nef that include
amino acid residues WL57–58, R77, D86, R106, I109, F121,
P130, EE154–155, or LL164–165 did not affect the down-modu-
lation of any of these target molecules by Nef (Table I). Data
obtained with Nef mutants were similar in human U937 cells and
mouse BMC-2 cells (Table I).
We next tested a variant of the F2-nef gene cloned and sequenced
from an independent HIV-1 isolate from the same patient. This variant
has a natural deletion of residues 55–61 of the Nef protein (D1-nef;
numbered according to the NL4-3 Nef sequence (Fig. 3A)). The D1-
Nef mutant induced no detectable down-modulation of cell surface
MHCI, despite remaining as efficient as the WT F2-Nef in inducing
the down-modulation of cell surface CD80 and CD86 (Fig. 3D). This
result suggested that the CD80/CD86 down-regulation property of
Nef is conserved and important for HIV infectivity. To explore this
further, we examined the Los Alamos HIV sequence database (ww-
w.hiv.lanl.gov/content/hiv-db/ALIGN_CURRENT/ALIGN-IN-
DEX.html) for patterns of Nef sequence variation. We focused on the
three regions identified by the data shown above. Among 822 Nef
sequences, there are six showing alterations in the 62–65 EEEE and
the (PXX)3 regions, critical for intracellular relocation of MHCI, but
not CD80/CD86. Five of these six alterations are in clinical isolates
from progressive HIV-mediated disease, while one is from a long-
term nonprogressing case. However, only two sequences show alter-
ations, both as deletions, in the 100–125 region critical for down-
regulation of all three molecules. At least one of these is from a long-
term nonprogressing case.
FIGURE 3. Distinct domains of Nef are crucial for down-modulation of
MHCI, CD80, and CD86. A, Amino acid sequence alignment and identi-
fication of the various Nef alleles used: NL4-3, F2-Nef, and D1-Nef. The
point mutations used are mapped in the appropriate sequence by color
coding, as shown for changes in the abilities to down-modulate MHCI,
CD80, and CD86. The deletion mutants constructed for F2-Nef are shown
as . Putative functional regions of Nef are indicated at the bottom of each
alignment set. Deleted residues are also identified (). All residues are
numbered according to the NL4-3 Nef sequence. B, Histograms are shown
for surface levels of indicated molecules on gated HAp U937 cells after
transfection to express HAp alone, or with WT NL4-3-Nef, NL4-3-Nef-
G2A, NL4-3-Nef-E4A, or NL4-3-Nef-PPPAAA. C, Histograms are shown
for surface levels of indicated molecules on gated eGFP U937 cells after
transfection to express eGFP alone, or with WT F2-Nef, F2-Nef-G2A,
F2-Nef-M20A, F2-Nef-100 (F2-Nef-2100), or F2-Nef-125 (F2-Nef-
2125). D, Histograms are shown for surface levels of indicated molecules
on gated eGFP U937 cells after transfection to express eGFP alone, or
with F2-Nef or D1-Nef. All gray-shaded curves indicate isotype controls.
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Down-modulation of CD80/CD86 is crucial for Nef-mediated
inhibition of naive T cell activation
Using a mouse cell system, we next tested whether the reduction
in cell surface CD80/CD86 levels by Nef is functionally significant
for the activation of naive T cells. For this, we cotransfected plas-
mids carrying F2-Nef and myc-p-tagged OVA into BMC-2 cells to
ascertain that a majority of OVA-myc-p-expressing transfected
cells also expressed Nef (Fig. 4, A and B). These cotransfected
BMC-2 cells were then used as stimulator APCs for either a T cell
hybridoma, B3Z, or for primary splenic cells from TCR-transgenic
mice (OT-I). Both B3Z and OT-I CD8 T cells express the same
TCR specific for an OVA peptide on MHCI (H-2Kb). A mixture of
anti-CD80 and anti-CD86 mAbs blocks the activation of OT-I
cells, but not of B3Z cells, showing their differential dependence
on costimulation (Fig. 4C). The presence of either F2-Nef or its
mutants did not affect the activation of B3Z cells (Fig. 4D). How-
ever, the response of OT-I cells was reduced not only by F2-Nef,
but also by D1-Nef, which is unable to affect MHCI levels (Fig.
4E). As a control, the G2A-Nef mutant that is incapable of down-
regulating MHCI, CD80, or CD86 did not affect this response (Fig.
4E). Similarly, stimulation of an OVA-specific MHCII-restricted T
cell hybridoma (13.8) by such transfected BMC-2 APCs was un-
affected by Nef (Fig. 4F). However, Nef expression reduced the
response induced by these APCs from naive T cells of OT-II mice
transgenic for an OVA-specific MHCII-restricted TCR (Fig. 4G).
Under these conditions, the OT-II cell proliferative responses re-
quire costimulation, while the 13.8 T cell hybridoma does not need
any costimulation (data not shown).
Nef associates with CD80 and CD86
The lower surface levels, but unchanged total cellular levels of
CD80 and CD86 coincident with Nef expression suggested that
Nef redistributes these proteins. We therefore examined whether
Nef colocalized subcellularly with these proteins in U937 and
BMC-2 cells by confocal microscopy, using expression vectors
containing the F2-nef, G2A-nef, D1-nef, and nef100 genes fused
in-frame to the eGFP gene. Transfection with an eGFP-expressing
vector was used as a control. All three proteins, MHCI, CD80, and
CD86, were predominantly redistributed intracellularly and colo-
calized with F2-Nef-eGFP, but not with control eGFP, G2A-Nef-
eGFP, or Nef100-eGFP. The Nef100-eGFP protein showed a
pattern of intracellular distribution similar to F2-Nef (Fig. 5A). The
D1-Nef protein colocalized intracellularly with CD80 and CD86,
but not with MHCI (Fig. 5A). Three-color confocal analysis of
Table I. Effects of Nef mutations on Nef-mediated down-modulation of
cell surface MHCI, CD80, and CD86 in monocytic cell lines
Mutants
U937 (Human Cells) BMC-2 (Mouse Cells)
MHCIa CD80a CD86a MHCIa CD80a CD86a
NL-4-3-nef (WTb)      
NL-4-3-nef-G2A      
NL-4-3-nef-WL57AA      
NL-4-3-nef-E4A      
NL-4-3-nef-R77A      
NL-4-3-nef-PPPAAA      
NL-4-3-nef-D86A      
NL-4-3-nef-R106A      
NL-4-3-nef-I109A      
F2-nef (WT)      
F2-nef-G2A      
F2-nef-M20A      
F2-nef-F121G    ND ND ND
F2-nef-P130A    ND ND ND
F2-nef-EE155AA    ND ND ND
F2-nef-LL164AA    ND ND ND
F2-nef-100      
F2-nef-125 ()c ()c ()c ()c ()c ()c
D1-nef      
a , Persistence of down-modulation ability; , loss of down-modulation ability.
b WT, wild type.
c (), Weak persistence of down-modulation ability.
FIGURE 4. CD80 and CD86 down-modulation by
Nef impairs activation of naive T cells. A and B, Show
the coexpression of OVA and Nef in transfected BMC-2
cells. Two-parameter plots (A) show frequencies of
OVA-myc-p expression in untransfected cells (), or
cells transfected to express OVA-myc alone or OVA-
myc F2-Nef, as indicated. The gates for OVA-myc-p
cells are also shown. Histograms (B) show staining
levels for F2-Nef-HAp in OVA-myc-p cells from
OVA-myc-transfected (thin line) or OVA-myc  F2-
Nef-HAp-transfected (thick broken line) cultures. The
gray-shaded curve is the isotype control. C, Shows
OVA-specific MHCI-restricted responses of either the T
cell hybridoma B3Z or primary TCR-transgenic OT-I
splenic T cells to OVA-transfected BMC-2 cells in the
presence () or absence () of Abs against CD80 and
CD86. Lines indicate relevant background values. D and
E, Show OVA-specific MHCI-restricted responses of ei-
ther the T cell hybridoma B3Z (D) or primary TCR-
transgenic OT-I splenic T cells (E) to BMC-2 cells var-
iously transfected, as indicated. F and G, Show the
OVA-specific MHCII-restricted responses of either the
T cell hybridoma 13.8 or the primary TCR-transgenic
OT-II splenic T cells, respectively, to BMC-2 cells var-
iously transfected, as indicated. All data are mean  SE
of triplicate cultures.
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these cells showed that Nef, MHCI, and CD80/CD86 colocalized
together at the same intracellular site in Nef-expressing BMC-2 or
U937 cells (Fig. 5, B and D). A quantitative analysis of the imag-
ing data showed a 5-fold loss of MHCI, CD80, and CD86 target
molecules from the cell surface due to Nef (Fig. 5, C and E). This
is comparable to the loss observed on flow cytometric analyses
(Figs. 1 and 2).
These colocalization results suggested that while inducing their
redistribution, Nef might bind to CD80 and CD86, either directly
or in a supramolecular complex. We examined this possibility by
immunoprecipitating F2-Nef from transfected BMC-2 cells and
Western blotting the immunoprecipitates for the presence of co-
precipitated mouse CD80 and CD86. Both CD80 and CD86 were
readily detectable to be coimmunoprecipitating with F2-Nef (Fig.
6A). Similarly, when CD80 and CD86 were immunoprecipitated,
Nef was found by Western blotting to be coimmunoprecipitating
with them in transfected cells (Fig. 6A). In U937 cells too, immu-
noprecipitating WT F2-Nef led to coprecipitation of CD80 and
CD86, and conversely, immunoprecipitation of CD80 or CD86
also brought down Nef (Fig. 6B). U937 cells were also transfected
FIGURE 5. HIV-1 Nef protein
colocalizes with CD80 and CD86
in transfected cells. A, U937 or
BMC-2 cells were transfected to
express eGFP, F2-Nef-eGFP, G2A-
Nef-eGFP, D1-Nef-eGFP, or
Nef100-eGFP (Nef2100) proteins.
The cells were fixed and stained for
the various molecules shown in the
colors indicated. B, BMC-2 cells
were transfected to express eGFP or
F2-Nef-eGFP proteins, fixed, and
stained for the various molecules
shown in the colors indicated. C,
Images of cell populations as rep-
resented in B were analyzed quan-
titatively for the fraction of total
cellular MHCI, CD80, or CD86
present at the cell surface in either
eGFP-expressing or F2-Nef-eGFP-
expressing BMC-2 cells. Data are
shown as percentage of total cellu-
lar protein present at the cell sur-
face (mean  SD; n 	 200). D,
U937 cells were transfected to ex-
press eGFP or F2-Nef-eGFP pro-
teins, and fixed and stained for the
various molecules shown in the
colors indicated. E, Images of cell
populations as represented in D
were analyzed quantitatively for the
fraction of total cellular MHCI,
CD80, or CD86 present at the cell
surface in either eGFP-expressing
or F2-Nef-eGFP-expressing U937
cells. Data are shown as percentage
of total cellular protein present at
the cell surface (mean  SD;
n 	 200). In all images, scale bars
are shown for each image (10 m),
and insets are at 2 magnification.
Insets, Show grayscale images for
each color as well as for merged
colors.
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with the truncated version of F2-Nef with residues from 100 on-
ward deleted (F2-Nef-100), which was unable to mediate any
significant down-regulation of MHCI, CD80, or CD86 (Fig. 3C).
Although the polyclonal anti-Nef Ab used for immunoprecipita-
tion and Western blotting could efficiently detect the smaller band
of F2-Nef-100, there was no coprecipitation seen between F2-
Nef100 and either CD80 or CD86 (Fig. 6C).
We also used cloned human CD80 and CD86 along with F2-Nef
in yeast two-hybrid assays to examine the possibility of direct
binding. The F2-Nef and CD80/CD86 genes were fused to the
DNA binding or activation domains, respectively, of the yeast
Gal4 protein gene. These plasmids were cotransformed into S. cer-
evisiae AH109 cells stably carrying the His3 and -gal reporter
constructs under control of a Gal4-responsive promoter. Only co-
transformation with the F2-Nef/CD80 and F2-Nef/CD86 pairs led
to growth of AH109 cells on medium lacking histidine (Fig. 6D).
These cells showed substantial induction of -gal activity over the
background for negative controls (Fig. 6E), confirming direct bind-
ing of Nef to CD80 and to CD86.
Discussion
In infected macrophages, Nef plays crucial roles, inhibiting cell
death to generate cellular reservoirs of persistent infection (7), and
inducing pathways for attraction and activation of T cells (9, 10) as
targets for further infection. A viral strategy of immune evasion is
likely to be useful in such a situation, and Nef is likely to play a
central role in such immune evasion as well. Nef down-modulates
cell surface MHCI and MHCII molecules to intracellular compart-
ments (13, 24). However, the effects of Nef on MHC molecules
alone cannot be expected to mediate efficient immune evasion.
This is because of the means used by Nef to remove MHC mol-
ecules from cell surfaces. Because MHCI and MHCII molecules
are removed from the cell surface with a t1/2 of 3 or 24 h, respec-
tively (25, 26), newly arriving peptide-loaded MHC molecules are
likely to remain on the cell surface for an adequate length of time
to provide T cell priming. Our functional data indeed suggest this
to be the case. Furthermore, Nef does not affect surface levels of all
MHCI isotypes (14), including mouse CD1d, a nonclassical MHC
molecule that can efficiently prime T cells (data not shown).
Our data now show that Nef also down-regulates the surface
expression of CD80 and CD86, major costimulatory molecules on
APCs that are crucial for T cell priming. These effects are seen in
macrophage lines of both mouse and human origin, as well as in
primary cultures of human murine macrophages and DCs, indicat-
ing these to be global effects. Human PBL-derived macrophages
infected with HIV-1 also show similar effects, establishing that
these are relevant consequences of infection rather than being seen
only with high Nef levels achieved with transfection. A previous
report suggesting that Nef expression in APCs does not affect ex-
pression of other cell surface molecules such as MHCI or CD80/
CD86 used an adenoviral vector that itself modifies the expression
of CD80/CD86, making it impossible to draw any conclusions
about the effect of Nef on CD80/CD86 levels (27). Nef is also
found as a secreted protein, and extracellular rNef can trigger DCs,
FIGURE 6. HIV-1 Nef protein
binds to CD80 and CD86 in trans-
fected cells. A–C, Western blot anal-
yses of immunoprecipitates from ly-
sates of BMC-2 cells (A) or U937
cells (B and C) transfected, as indi-
cated. The Ab specificities used for
immunoprecipitation (IP) and West-
ern blotting (WB) are shown (F2-
Nef-100: Nef2100). D, Yeast two-
hybrid analysis in AH109 cells using
the F2-nef gene in the activation do-
main (AD) vector plasmid and full-
length human CD80 or CD86 genes
in the DNA binding domain (BD)
vector plasmid, or control plasmids
with no inserts (), or positive con-
trol plasmids containing the SNF1-
SNF4 genes. AH109 yeast cells used
for transformation were grown on
plates of rich yeast extract/peptone/
dextrose medium (His) or His-defi-
cient medium without leucine, tryp-
tophan, and histidine (His). The
growth pattern on plates is shown
with plating done according to the
template shown, which indicates the
inserts in the AD:BD. The activation
of the reporter -gal gene in His
medium is shown in E as enzymatic
activity in triplicate cultures
(mean  SE).
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leading to modest up-regulation of surface CD80 and CD86 (28),
underlining the pleiotropy of the effects of Nef on APCs. Together,
the role of Nef appears to incorporate both APC-mediated by-
stander T cell activation and immune evasion to ensure that, while
the virus has a supply of activated T cells in peripheral lymphoid
organs to spread to, the virus-specific T cells among these recruited
populations are not allowed to receive Ag-specific priming
triggers.
The down-modulation of CD80 and CD86 by Nef is specific,
because no changes could be detected in the surface levels of other
molecules such as TfR, CD11b, CD54, or CD40. Furthermore, the
total cellular levels of MHCI, CD80, and CD86 in Nef-expressing
cells are not altered, indicating that the effects of Nef on the cell
surface levels of these molecules are due to altered trafficking.
Although the nef gene used in most of our experiments shown in
this study is from a clinical isolate of HIV-1 subtype C, redistri-
bution of CD80 and CD86 is also mediated by the NL4-3 Nef
protein from HIV-1 subtype B. Significantly, we have identified a
Nef variant (D1-Nef) from a clinical isolate of HIV-1 subtype C
that has lost the ability to down-regulate MHCI, but can still down-
regulate CD80 or CD86. This observation underlines the impor-
tance of Nef-mediated CD80 and CD86 modulation in vivo. An
analysis of Nef sequence variation in the HIV sequence database is
also consistent with this possibility. Sequence variation in regions
important for MHCI down-modulation alone is somewhat more
permissive than in a region critical for down-modulation of MHCI
as well as CD80 and CD86, suggesting the likely importance of
CD80/86 down-modulation in HIV pathology.
All relocation effects of Nef on MHCI, CD80, and CD86 are lost
with a mutation that prevents Nef myristoylation (G2A (24)), in-
dicating that membrane recruitment of the Nef protein is necessary
for its effects on the trafficking of various target cell surface mol-
ecules. Serial deletions of the C terminus of the F2-Nef protein
indicate that, while the 100- to 125-aa region is critical for reduc-
tion in MHCI, CD80, and CD86 levels, residues beyond 125 are
also needed for optimal function of the Nef protein. Mutations at
R77, D86, R106, I109, or LL164–165 do not affect the down-
modulation of any target molecules by Nef, suggesting the poten-
tial functions hypothesized at these sites, such as binding of SH3
domains, PAK1/2 or AP1/2/3, are not likely to be involved in these
trafficking functions of Nef.
Comparisons between F2-Nef and NL4-3-Nef raise some im-
portant issues regarding the role of specific domains of Nef in
internalization. The EEEE sequence at residues 62–65 in NL4-3-
Nef has been shown to be critical for MHCI down-regulation (24).
In F2-Nef, which remains competent for MHCI relocation, the
corresponding residues are EDEGE. However, their modification
to DEDGE in D1-Nef prevents MHCI relocation, identifying im-
portant residues within this critical area. However, this modifica-
tion does not affect CD80/86 down-modulation.
Further analysis of the effects of Nef mutants reveals distinct
roles for different Nef residues in mediating the down-modulation
of MHCI vs CD80 or CD86. Specifically, the E4A (PACS-1 re-
cruitment domain) and the PPPAAA (an SH3 binding domain)
mutants of NL4-3 Nef, as well as the D1 natural mutant of F2-Nef,
which is also devoid of the PACS-1 recruiting domain, do not
down-modulate MHCI, but efficiently reduce surface levels of
CD80 and CD86, again emphasizing the separation between
MHCI-directed vs CD80/CD86-directed effects of Nef. Although
Nef appears to interact weakly and transiently with specific MHCI
molecules (29), our data indicate that Nef binds strongly and di-
rectly to both human and mouse CD80 and CD86, suggesting a
possible mechanism for recruitment of cellular signaling and traf-
ficking pathways to achieve the cellular redistribution of CD80 and
CD86. This is supported by the finding that a truncated version of
Nef that cannot down-modulate CD80 or CD86 cannot bind to
these molecules either.
Importantly, this function of Nef is involved in preventing the
activation of naive T cells, providing evidence for the functional
significance of our findings in the mechanism of HIV immune
evasion. Although Nef down-modulates MHC molecules, this re-
duction is slow (data not shown). Thus, when T cell activation
assays are conducted within 24 h of Nef transfection, presentation
of APC endogenous Ag to both MHCII-restricted and MHCI-re-
stricted T cell hybridomas is unaffected by the presence of Nef in
these APCs. However, these same APCs are extremely poor acti-
vators of naive primary CD4 and CD8 T cells, consistent with
Nef-mediated loss of costimulatory function as a major modulator
of immune priming. This interpretation is further emphasized
when the D1-Nef mutant, which has no effect on MHCI levels, is
used in assays with naive CD8 T cells, reinforcing the importance
of CD80/86 down-modulation effects of Nef. Together, these data
suggest a significant role for Nef-mediated loss of costimulation in
immune evasion during HIV infection.
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